Is it October yet?
While summer winds down, we’re all looking to the coming legalization date in the fall. In the meantime companies and schools are getting themselves ready for the end of prohibition and the subsequent boom of the new market.
To keep you informed we’ve rounded up the best news stories of the week from the cannabis space.
Certain medical dispensaries across Canada are uncertain of their future. Currently, Canadian dispensaries are selling medicinal products that will not be available for recreational sales under the current Cannabis Act.
Individuals with doctors notes that purchase cannabis will not be able to use the upcoming government stores for their specific needs. Medicinal patients require certain concentrated products to remedy their conditions, these users will not be able to use the recreational stores. Because omitted from Canada’s legislation plan are highly-concentrated products with THC and/or CBD Oil.
A medical user with epilepsy typically requires 2 grams of weed to deal with seizures. For some, this amount of flower is a lot to smoke. Many other conditions such as chronic pain, anxiety relief, and cancer treatment, also require a much larger than usual intake of cannabis to feel the benefits.
Medical only dispensaries like MJN Express are looking for answers.
“Hopefully everyone can get what they need, and in the long-term recreational legalization will be fantastic,” the company said via press release. “Out the gate, it doesn’t look like it.”
A recent study, published in the Journal of Alzheimer’s Disease, researchers describe how they identified “patterns of ageing” linked to cannabis usage from a series of brain scans. The study did not focus specifically on cannabis’ impact on the brain, but did find that use of the substance in those with other preexisting conditions increased the rate by which the brain aged.
Subjects of the study had psychiatric conditions such as attention deficit hyperactivity disorder, schizophrenia, and bipolar disorder.
Alcohol was also found to have a similar effect during the same study.
The cannabis industry is about to catch fire in Canada and Saskatchewan Polytechnic sees a coming demand for a major in the budding industry.
“We are working on new programming that would offer students an education in both the retail sales side and production or cultivation of cannabis,” Anne Neufeld, provost and academic vice-president for the school, said.
There are already several post-secondary institutions across Canada that offer cannabis programming, specifically for commercial production and cultivation of medicinal marijuana.
“We recognize that we can take that programming and leverage it,” Neufeld said. “So, we’re looking at the retail side of things and making sure all the legislative requirements would be understood and quality assurance steps are taken in addition to the production side of things.”
The developmental work of the cannabis education programming is part of the school’s multi-year business plan and won’t likely be launched until the 2020 school year.
When cannabis becomes legal in the fall, people in St. Albert, Alberta won’t be allowed to use the drug in public.
St. Albert council voted 6-1 at its meeting on Monday in favour of a citywide ban that prohibits smoking, vaping or consuming cannabis outside of private residences.
Municipal politicians acted on the advice of Alberta Health Services officials who joined them in the council chambers, Mayor Cathy Heron said Tuesday morning.
“Their suggestion was it’s easier to go very restrictive now and loosen it up as we become more aware and more educated and the fear and the unknown starts to dissipate,” she said.
“But it would be much harder to go the other way. So if we were very loose with our regulations, it would be hard to clamp down if we felt we had made a mistake.
“We will err on the side of caution.”
According to data published by Research and Markets, the North American legal cannabis market value is projected to reach approximately USD 35 Billion by 2023. The legal market has already surpassed the $8 Billion mark in terms of value in 2017. The report also specifies that cannabis is gaining prominence in the North American region because of increasing favourable views in regards of products for both recreational and medical uses.
As a result of legalization and indications of demand, an influx of investments into research and development has occurred, growing both the medical and retail potential of green products.
Aurora Cannabis and McGill University recently announced the launch of an international collaborative medical research project that will examine the therapeutic impact and health outcomes of cannabidiol (CBD) oil as a therapy for chronic pain and related anxiety and depression.
The three-year translational collaborative research project will investigate the pain relief properties of CBD oil by exploring its mechanism of action in pain and associated depression and anxiety.
“Based on our extensive experience with more than 60,000 registered Canadian patients, we believe CBD to be one of the most impactful medical compounds to become legally available to people in need of non-addictive therapies to treat pain,” stated Terry Booth, Chief Executive Officer. “Our support for and involvement with this project underlines Aurora’s leadership in the medical cannabis space, as well as our long-term commitment to a science-based approach to deepen understanding of this amazing substance.”